Each uncoated tablet contains Pioglitazone 15 mg + Metformin Hydrochloride SR 500 mg.

Pionorm-M Tablets combine Pioglitazone and Metformin to provide dual-action glycaemic control in adults with type 2 diabetes mellitus. Pioglitazone improves insulin sensitivity by reducing peripheral and hepatic insulin resistance, while Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and enhances peripheral glucose utilization. The sustained-release formulation of metformin improves gastrointestinal tolerability and supports better patient compliance, making Pionorm-M an effective second-line therapy when monotherapy is inadequate.

Pionorm-M Tablets are indicated as second-line therapy for the management of type 2 diabetes mellitus in adults when adequate glycaemic control is not achieved with lifestyle modification or monotherapy.

Pioglitazone is a thiazolidinedione antidiabetic agent that improves insulin sensitivity in peripheral tissues and the liver, resulting in increased insulin-dependent glucose disposal and reduced hepatic glucose output. Metformin is an antihyperglycaemic agent that lowers both basal and postprandial plasma glucose by decreasing hepatic glucose production, reducing intestinal glucose absorption, and improving peripheral insulin sensitivity through enhanced glucose uptake and utilization. Together, these agents provide complementary mechanisms for improved glycaemic control.

The recommended dosage is one tablet once daily with a meal, or as directed by the physician. Dosage should be individualized based on the patient's glycaemic response and clinical condition.

Pionorm-M Tablets are contraindicated in patients with hypersensitivity to pioglitazone, metformin, or any component of the formulation; cardiac failure or a history of cardiac failure (NYHA Class I–IV); hepatic impairment; diabetic ketoacidosis; active bladder cancer or a history of bladder cancer; unexplained haematuria; and acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma.